Fate Therapeutics Inc (FATE):企業の財務・戦略的SWOT分析

◆英語タイトル:Fate Therapeutics Inc (FATE) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15509
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Fate Therapeutics Inc (FATE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidates. Its immuno-oncology product candidates include adaptive NK, pluripotent cell-derived cancer immunotherapies, and engineered CAR and TCR T- cell immunotherapies. Its products are derived from pluripotent cells. Fate Therapeutics uses ex vivo cell programming approach to include cell-surface proteins, rapid and supra-physiologic activation or inhibition of therapeutically-relevant genes, and to regulate the therapeutic function. The company’s immuno-regulatory cellular therapies promote immune system homeostasis for patients undergoing hematopoietic cell transplantation and immune disorders. Fate Therapeutics is headquartered in San Diego, California, the US.

Fate Therapeutics Inc Key Recent Developments

Mar 18,2019 Fate Therapeutics announces the appointment of Karin Jooss, Ph.D. to its board of directors
Mar 05,2019 Fate Therapeutics reports fourth quarter and full year 2018 financial results and highlights operational progress
Feb 20,2019 Fate Therapeutics names Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation
Dec 04,2018 12/4/18 – Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Fate Therapeutics Inc – Key Facts
Fate Therapeutics Inc – Key Employees
Fate Therapeutics Inc – Key Employee Biographies
Fate Therapeutics Inc – Major Products and Services
Fate Therapeutics Inc – History
Fate Therapeutics Inc – Company Statement
Fate Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Fate Therapeutics Inc – Business Description
R&D Overview
Fate Therapeutics Inc – Corporate Strategy
Fate Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Fate Therapeutics Inc – Strengths
Fate Therapeutics Inc – Weaknesses
Fate Therapeutics Inc – Opportunities
Fate Therapeutics Inc – Threats
Fate Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Fate Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 18, 2019: Fate Therapeutics announces the appointment of Karin Jooss, Ph.D. to its board of directors
Mar 05, 2019: Fate Therapeutics reports fourth quarter and full year 2018 financial results and highlights operational progress
Feb 20, 2019: Fate Therapeutics names Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation
Dec 04, 2018: 12/4/18 – Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting
Nov 30, 2018: Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy
Nov 01, 2018: Fate Therapeutics reports third quarter 2018 financial results and highlights operational progress
Oct 04, 2018: Fate Therapeutics names Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations
Aug 06, 2018: Fate therapeutics announces second quarter 2018 financial results and highlights operational progress
May 10, 2018: Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress
Mar 05, 2018: Fate Therapeutics Announces Fourth Quarter 2017 Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Fate Therapeutics Inc, Key Facts
Fate Therapeutics Inc, Key Employees
Fate Therapeutics Inc, Key Employee Biographies
Fate Therapeutics Inc, Major Products and Services
Fate Therapeutics Inc, History
Fate Therapeutics Inc, Subsidiaries
Fate Therapeutics Inc, Key Competitors
Fate Therapeutics Inc, Ratios based on current share price
Fate Therapeutics Inc, Annual Ratios
Fate Therapeutics Inc, Annual Ratios (Cont...1)
Fate Therapeutics Inc, Interim Ratios
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Fate Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Fate Therapeutics Inc, Performance Chart (2014 - 2018)
Fate Therapeutics Inc, Ratio Charts
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Fate Therapeutics Inc (FATE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • OPG Power Ventures Plc (OPG):電力:M&Aディール及び事業提携情報
    Summary OPG Power Ventures Plc (OPG) is an electric utility. It develops, owns, operates, and maintains private sector power projects in India. The company produces electricity from coal source. OPG operates coal-fired power plants in Tamil Nadu and Gujarat. It sells the electricity generated from i …
  • Ra Medical Systems Inc (RMED):医療機器:M&Aディール及び事業提携情報
    Summary Ra Medical Systems Inc (Ra Medical Systems) is a medical device company that develops, designs, and commercializes excimer laser systems for the treatment of cardiovascular and dermatologic diseases. The company’s technology provides operational versatility and dose customization. Its produc …
  • Pure Technologies Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Pure Technologies Ltd. (Pure Technologies) develops technologies for inspection, monitoring and management of physical infrastructure such as buildings, water and hydrocarbon pipelines, and bridges. It provides proprietary monitoring equipment for pipelines, bridges and structures; technical …
  • Gridsum Holding, Inc. (GSUM):企業の財務・戦略的SWOT分析
    Gridsum Holding, Inc. (GSUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • IDT Corporation:企業の戦略・SWOT・財務情報
    IDT Corporation - Strategy, SWOT and Corporate Finance Report Summary IDT Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Covance Inc:企業の戦略的SWOT分析
    Covance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Cardiac Science Corp:企業の戦略的SWOT分析
    Cardiac Science Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Nestle USA, Inc.:企業の戦略・SWOT・財務情報
    Nestle USA, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nestle USA, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Qatar Airways Group Q.C.S.C.
    Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report Summary Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Coherus BioSciences Inc (CHRS):企業の財務・戦略的SWOT分析
    Summary Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used …
  • Bank Hapoalim BM:企業の戦略・SWOT・財務情報
    Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report Summary Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • AstraZeneca Plc (AZN)-医療機器分野:企業M&A・提携分析
    Summary AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and n …
  • Precision Drilling Corp (PD):企業の財務・戦略的SWOT分析
    Precision Drilling Corp (PD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Corcept Therapeutics Inc (CORT):企業の財務・戦略的SWOT分析
    Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Richardson Electronics Ltd (RELL):企業の財務・戦略的SWOT分析
    Summary Richardson Electronics Ltd (Richardson Electronics) manufactures electron tube. It offers engineered solutions, power grid and microwave tubes and consumables, displays, flat panel detector solutions and parts for diagnostic imaging equipment, power conversion and RF and microwave components …
  • CRH Medical Corp (CRH):医療機器:M&Aディール及び事業提携情報
    Summary CRH Medical Corp (CRH Medical), formerly Medsurge Medical Products Corp, is a medical device company that offers treatment of hemorrhoids. The company provides CRH O’Regan System, a hemorrhoid technology for treating hemorrhoid. It offers topical ointments and creams including preparation H …
  • Sabine Oil & Gas Corporation-石油・ガス分野:企業M&A・提携分析
    Summary Sabine Oil & Gas Corporation (Sabine Oil), formerly known as Forest Oil Corporation is an independent oil and gas company. The company focuses on acquisition, exploitation, development and exploration of oil and natural gas properties onshore in the US. Its core areas of operations include E …
  • Landstar System, Inc.:企業の戦略・SWOT・財務分析
    Landstar System, Inc. - Strategy, SWOT and Corporate Finance Report Summary Landstar System, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Bank of New York Mellon Corporation:企業のM&A・事業提携・投資動向
    The Bank of New York Mellon Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Bank of New York Mellon Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …
  • Beactica AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Beactica AB (Beactica) is a drug discovery company develops a pipeline of novel and mechanistically defined small molecule therapeutics. The company offers wide range of services such as fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate ana …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆